Rhythm Pharmaceuticals Inc $RYTM

Recent News (3)

• Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan GlobeNewswire · 24 Aug 2026 -- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan --  -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
• Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can Yahoo Finance · 23 Aug 2026 Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
• Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update GlobeNewswire · 04 Aug 2026 -- U.S. launch of IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second quarter 2026…